Project Grant R43HL123069

Federal Project Grant Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded Massachusetts General Hospital $247,500 under the Cardiovascular Diseases Research program (CFDA 93.837) to validate a positron emission tomography (PET) imaging probe targeting CD206-positive macrophages for idiopathic pulmonary fibrosis (IPF) diagnosis and monitoring. The project, which commenced August 15, 2025 and concludes July 31, 2027, aims to develop and validate a PET imaging agent that shares...

The National Heart, Lung, and Blood Institute awarded the University of Utah $705,239 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct research on PET imaging as a tool to define mechanisms and stratify risk in arrhythmogenic cardiomyopathy. The recipient will integrate molecular imaging, immune profiling, and cardiac physiology in mechanistically relevant mouse models to test the hypothesis that positron emission tomography using...

The National Institute of Biomedical Imaging and Bioengineering awarded Georgia TECH Research Corp $603,818 on April 1, 2026, under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) to develop and demonstrate a combined intravascular ultrasound (IVUS) and fractional flow reserve (FFR) microcatheter for guiding complex percutaneous coronary interventions. The project delivers a 2.5F coronary microcatheter integrating an FFR sensor...

The National Heart, Lung, and Blood Institute awarded $1.559 million to the University of Pittsburgh on July 10, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to validate chemokine-like receptor 1 (CMKLR1)-targeted positron emission tomography as a noninvasive imaging tool for monitoring myocardial inflammation and predicting post-myocardial infarction heart failure risk. The research addresses a clinical gap in identifying patients with sustained macrophage-driven...

The National Heart, Lung, and Blood Institute awarded Icahn School of Medicine at Mount Sinai $1.669 million on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for data-consistent motion-correction reconstruction of PET/MR imaging targeting coronary atherosclerotic plaque activity. The research addresses motion artifacts that degrade spatial resolution and quantitative accuracy in coronary PET imaging, particularly for low-count tracers such as 68GA-DOTATATE....

The National Institutes of Health National Heart Lung and Blood Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $121,345 under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2026. The award funds development of positron emission tomography (PET) imaging of oxidized collagen as a biomarker for myocardial fibrosis in heart failure with preserved ejection fraction (HFpEF). The project focuses on targeted PET imaging probes that bind...

The National Heart, Lung, and Blood Institute awarded Beth Israel Deaconess Medical Center, Inc. $848,141 on July 1, 2026, to develop and validate cardiac magnetic resonance (CMR) imaging diagnostic criteria for coronary microvascular dysfunction (MVD) under the Cardiovascular Diseases Research program (CFDA 93.837). The research defines and validates CMR-based diagnostic criteria for MVD using invasive coronary function testing as the reference standard, evaluates the correlation and diagnostic...

The National Heart, Lung, and Blood Institute awarded The Washington University $1,514,143 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and validate PET imaging strategies for early detection of chemotherapy-induced cardiotoxicity. The award funds research on 68GA-GALMYDAR, a novel positron emission tomography tracer designed to provide noninvasive, early functional assessment of myocardial mitochondrial status. Cardiotoxicity from...

The National Heart, Lung, and Blood Institute awarded Yale University $445,000 under CFDA 93.837 (Cardiovascular Diseases Research) on August 1, 2026, to develop deuterium metabolic imaging (DMI) as a non-invasive diagnostic tool for hibernating myocardium in coronary artery disease patients. The award is classified as a Project Grant under NIH assistance type R21HL184055. The research addresses a clinical gap: roughly 4 million Americans with heart failure stemming from coronary artery...

The National Heart, Lung, and Blood Institute awarded the University of Virginia $802,973 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop rapid point-of-care molecular imaging of immune activation in acute coronary syndrome and acute myocarditis using targeted microbubble contrast agents. The project applies myocardial contrast echocardiography with phosphatidylserine-incorporating lipid microbubbles (MB-PS) to detect inflammatory activation from...